Investigation of FANCA mutations in Greek patients

Anticancer Res. 2013 Aug;33(8):3369-74.

Abstract

Background: Fanconi anemia (FA) is a rare genetic disease characterized by considerable heterogeneity. Fifteen subtypes are currently recognised and deletions of the Fanconi anemia complementation group A (FANCA) gene account for more than 65% of FA cases. We report on the results from a cohort of 166 patients referred to the Department of Medical Genetics of Athens University for genetic investigation after the clinical suspicion of FA.

Materials and methods: For clastogen-induced chromosome damage, cultures were set up with the addition of mitomycin C (MMC) and diepoxybutane (DEB), respectively. Following a positive cytogenetic result, molecular analysis was performed to allow identification of causative mutations in the FANCA gene.

Results: A total of 13/166 patients were diagnosed with FA and 8/13 belonged to the FA-A subtype. A novel point mutation was identified in exon 26 of FANCA gene.

Conclusion: In our study 62% of FA patients were classified in the FA-A subtype and a point mutation in exon 26 was noted for the first time.

Keywords: FANCA gene; Fanconi anemia; Greek patients; cytogenetic and molecular investigation; mutation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Base Sequence
  • Child
  • Child, Preschool
  • Cytogenetic Analysis
  • DNA Mutational Analysis
  • Exons / genetics
  • Fanconi Anemia / complications
  • Fanconi Anemia / genetics*
  • Fanconi Anemia Complementation Group A Protein / genetics*
  • Greece
  • Humans
  • Infant
  • Metaphase / drug effects
  • Metaphase / genetics
  • Mitomycin / pharmacology
  • Molecular Sequence Data
  • Point Mutation / genetics*
  • Thumb / abnormalities
  • Twins, Dizygotic / genetics
  • Young Adult

Substances

  • FANCA protein, human
  • Fanconi Anemia Complementation Group A Protein
  • Mitomycin